Biotech · Private company
Calcilytix Therapeutics, Inc., a BridgeBio company
Track this companyFree. Adds Calcilytix Therapeutics, Inc., a BridgeBio company to your Dealase workspace and tells you when its record changes.
Clinical trials54 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- EncaleretPhase 3 · Autosomal Dominant Hypocalcemia (ADH)ClinicalTrials.gov · fetched Nov 12, 2026
- EncaleretPhase 3 · Autosomal Dominant Hypocalcemia Type 1 (ADH1)ClinicalTrials.gov · fetched Nov 12, 2026
- EncaleretPhase 3 · HypoparathyroidismClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic HypoparathyroidismPHASE3 · RECRUITING · started Aug 31, 2026ClinicalTrials.gov NCT07805356 · fetched Nov 12, 2026
- Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)PHASE2_PHASE3 · RECRUITING · started Jan 30, 2026ClinicalTrials.gov NCT07080385 · fetched Nov 12, 2026
- Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1PHASE3 · ACTIVE_NOT_RECRUITING · started Jan 6, 2023ClinicalTrials.gov NCT05680818 · fetched Nov 12, 2026
- ADH1 and ADH2 Disease Monitoring Study (DMS)ACTIVE_NOT_RECRUITING · started Jan 20, 2022ClinicalTrials.gov NCT05227287 · fetched Nov 12, 2026
- Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1PHASE2 · COMPLETED · started Sep 20, 2020ClinicalTrials.gov NCT04581629 · fetched Nov 12, 2026